Identification of novel and improved antimitotic agents derived from noscapine

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7096-7098

  Anderson, James T ^a   Ting, Anthony E ^a   Boozer, Sherry ^a   Brunden, Kurt R ^a   Crumrine, Chris ^a   Danzig, Joel ^a   Dent, Tom ^a   Faga, Laurel ^a   Harrington, John J ^a   Hodnick, William F ^a   Murphy, Steven M ^a   Pawlowski, Gary ^a   Perry, Robert ^a   Raber, Amy ^a   Rundlett, Stephen E ^a   Stricker Krongrad, Alain ^a   Wang, Jianmin ^a   Bennani, Youssef L ^a  

^a ATHERSYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; ANTIMITOTIC AGENT; DNA; NOSCAPINE; PHENOL; TRIFLUOROMETHANESULFONIC ACID; TUBULIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DEMETHYLATION; DIASTEREOISOMER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEREOCHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HELA CELLS; HUMANS; MICE; MICROTUBULES; NOSCAPINE; STEREOISOMERISM; TUBULIN; TUBULIN MODULATORS;

EID: 28544446298     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050674q     Document Type: Article

References (28)

1. (a) Jordan, M. A.; Wilson L. Microtubules as a Target for Anticancer Drugs. Nat. Rev. Cancer 2004, 4, 253-265.
2. (b) Wilson, L.; Jordan, M. A. Microtubule Dynamics: Taking Aim at a Moving Target. Chem. Biol. 1995, 2, 569-573.
3. Li, Q.; Sham, H. L. Discovery and Development of Antimitotic Agents That Inhibit Tubulin Polymerization for the Treatment of Cancer. Expert Opin. Ther. Pat. 2002, 12 (11), 1663-1702.
4. Fleming, S.; Lucas, F.; Schofield, M. A Therapeutic Area Review of Oncology Products and Players. Expert Opin. Emerging Drugs 2001, 6 (2), 317-329.
5. Simon, S. M.; Schindler, M. Cell Biological Mechanisms of Multidrug Resistance in Tumors. Proc. Natl. Acad. Sci U.S.A. 1994, 91, 3497-3504.
6. Van Zuylen, L.; Verweij, J.; Sparreboom, A. Role of Formulation Vehicles in Taxane Pharmacology. Invest. New Drugs 2001, 19, 125-141.
7. Dahlstrom, B.; Mellstrand, T.; Lofdahl, C.-G.; Johansson, M. Pharmakokinetic Properties of Noscapine. Eur. J. Clin. Pharmacol. 1982, 22, 535-539.
8. (a) Lettre, H. Synergists and Antagonists of Mitotic Poisons. Ann. N. Y. Acad. Sci. 1954, 58, 1264-1275.
9. (b) Lettre, H.; Albrecht, M. Narcotin, ein Mitosegift (Narcotine, a Mitotic Poison). Naturwissenschaften 1942, 30, 184-185.
10. (a) Ye, K.; Ke, Y.; Keshava, N.; Shanks, J.; Kapp, J. A.; Tekmal, R. R.; Petros, J.; Joshi, H. C. Opium Alkaloid Noscapine Is an Antitumor Agent That Arrests Metaphase and Induces Apoptosis in Dividing Cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 1601-1606.
11. (b) Joshi, H. C.; Zhou, J. Noscapine and Analogues as Potential Chemotherapeutic Agents. Drug News Perspect. 2000, 13 (9), 543-546.
12. Ke, Y.; Ye, K.; Grossniklaus, H. E.; Archer, D. R.; Joshi, H. C.; Kapp, J. A. Noscapine Inhibits Tumor Growth with Little Toxicity to Normal Tissues or Inhibition of Immune Responses. Cancer Immunol. Immunother. 2000, 49, 217-225
13. Landen, J. W.; Lang, R.; McMahon, S. J.; Rusan, N. M.; Yvon, A.-M.; Adams, A. W.; Sorcinelli, M. D.; Campbell, R.; Bonaccorsi, P.; Ansel, J. C.; Archer, D. R.; Wadsworth, P.; Armstrong, C. A.; Joshi, H. C. Noscapine Alters Microtubule Dynamics in Living Cells and Inhibits the Progression of Melanoma. Cancer Res. 2002, 62, 4109-4114.
14. Anderson, J. T.; Ting, A. E.; Boozer, S.; Brunden, K. R.; Danzig, J.; Dent, T.; Harrington, J. J.; Murphy, S. M.; Perry, R.; Raber, A.; Rundlett, S. E.; Wang, J.; Wang, N.; Bennani, Y. L. Discovery of S-Phase Arresting Agents Derived from Noscapine. J. Med. Chem. 2005, 48, 2756-2758.
15. Tumey, L. N.; Bom, D.; Huck, B.; Gleason, E.; Wang, J.; Silver, D.; Brunden, K.; Boozer, S.; Rundlett, S.; Sherf, B.; Murphy, S.; Dent, T.; Leventhal, C.; Bailey, A.; Harrington, J.; Bennani, Y. L. The Identification and Optimization of a N-Hydroxy Urea Series of Flap Endonuclease 1 Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 277-281.
16. (a) Wolfe, J. P.; Buchwald, S. L. Palladium-Catalyzed Amination of Aryl Triflates. J. Org. Chem. 1997, 62, 1264-1267. Louie, J.; Driver, M. S.; Hamann, B. C. Personal communication.
17. (b) Hartwig, J. F. Palladium-Catalyzed Amination of Aryl Triflates and Importance of Triflate Addition Rate. J. Org. Chem. 1997, 62, 1268-1273.
18. Old, D. W.; Wolfe, J. P.; Buchwald, S. L. A Highly Active Catalyst for Palladium-Catalyzed Cross-Coupling Reactions: Room-Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides. J. Am. Chem. Soc. 1998, 120, 9722-9723.
19. Schmidhammer, H.; Klotzer, W. Neue Reaktionen an Phthalidisochinolinalkaloiden. Alkoxytauschreaktionen und Isomerisierungen an α- und β-Narcotin (New Reactions of Phthalidoisoquinoline Alkaloids. Alkoxy Exchange Reactions and Isomerizations of α- and β-Narcotine).Arch. Pharm. (Weinheim, Ger.) 1978, 311, 664-671.
20. Marshall, M. A.; Pyman, F. L.; Robinson, R. Stereoisomerides of Narcotine and Hydrastine. J. Chem. Soc. 1934, 1315-1320.
21. 2O in large-scale reactions.
22. Kuwano, R.; Utsunomiya, M.; Hartwig, J. F. Aqueous Hydroxide as a Base for Palladium-Catalyzed Animation of Aryl Chlorides and Bromides. J. Org. Chem. 2002, 67, 6479-6486.
23. Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates. J. Org. Chem. 2000, 65, 1158-1174.
24. Lee, S.; Jorgensen, M.; Hartwig, J. F. Palladium-Catalyzed Synthesis of Arylamines from Aryl Halides and Lithium Bis(trimethylsilyl)amide as an Ammonia Equivalent. Org. Lett. 2001, 3, 2729-2732.
25. Hartwig, J. F.; Kawatsura, M.; Hauck, S. I.; Shaughnessy, K. H.; Alcazar-Roman, L. M. Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand. J. Org. Chem. 1999, 64, 5575-5580.
26. Zim, D.; Buchwald, S. L. An Air and Thermally Stable One-Component Catalyst for the Amination of Aryl Chlorides. Org. Lett. 2003, 5, 2413-2415.
27. Zhou, J.; Gupta, K; Aggarwal, A. R.; Chandra, R.; Panda, D.; Joshi, H. C. Brominated Derivatives of Noscapine Are Potent Microtubule-Interfering Agents That Perturb Mitosis and Inhibit Cell Proliferation. Mol. Pharmacol. 2003, 63, 799-807.
28. Saa, J. M.; Dopico, M.; Martorell, G.; Garcia-Raso, A. Deoxygenation of Highly Hindered Phenols. J. Org. Chem. 1990, 55, 991-995.